Associations	O
of	O
Amylin	B-GP
with	O
Inflammatory	O
Markers	O
and	O
Metabolic	B-DS
Syndrome	I-DS
in	O
Apparently	O
Healthy	O
Chinese	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
YL	O
XL	O
XH	O
LS	O
.	O

Performed	O
the	O
experiments	O
:	O
XH	O
LS	O
ZL	O
HM	O
ZY	O
HL	O
PJ	O
DY	O
HW	O
.	O

Analyzed	O
the	O
data	O
:	O
XH	O
LS	O
ZY	O
XY	O
.	O

Wrote	O
the	O
paper	O
:	O
XH	O
LS	O
YL	O
XL	O
.	O

Background	O

Cellular	O
and	O
animal	B-OG
studies	O
implicate	O
multiple	O
roles	O
of	O
amylin	B-GP
in	O
regulating	O
insulin	B-GP
action	O
,	O
glucose	O
and	O
lipid	O
metabolisms	O
.	O

However	O
,	O
the	O
role	O
of	O
amylin	B-GP
in	O
obesity	B-DS
related	O
metabolic	B-DS
disorders	I-DS
has	O
not	O
been	O
thoroughly	O
investigated	O
in	O
humans	B-OG
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
distribution	O
of	O
circulating	O
amylin	B-GP
and	O
its	O
association	O
with	O
metabolic	B-DS
syndrome	I-DS
(	O
MetS	B-DS
)	O
and	O
explore	O
if	O
this	O
association	O
is	O
influenced	O
by	O
obesity	B-DS
,	O
inflammatory	O
markers	O
or	O
insulin	B-DS
resistance	I-DS
in	O
apparently	O
healthy	O
Chinese	O
.	O

Methods	O

A	O
population	O
-	O
based	O
sample	O
of	O
1	O
,	O
011	O
Chinese	O
men	O
and	O
women	O
aged	O
35	O
–	O
54	O
years	O
was	O
employed	O
to	O
measure	O
plasma	O
amylin	B-GP
,	O
inflammatory	O
markers	O
(	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
[	O
CRP	B-GP
]	O
and	O
interleukin	B-GP
-	I-GP
6	I-GP
[	O
IL	B-GP
-	I-GP
6	I-GP
]),	O
insulin	B-GP
,	O
glucose	O
and	O
lipid	O
profiles	O
.	O

MetS	B-DS
was	O
defined	O
according	O
to	O
the	O
updated	O
National	O
Cholesterol	O
Education	O
Program	O
Adult	O
Treatment	O
Panel	O
III	O
criteria	O
for	O
Asian	O
-	O
Americans	O
.	O

Results	O

Plasma	O
amylin	B-GP
concentrations	O
were	O
higher	O
in	O
overweight	O
/	O
obese	O
participants	O
than	O
normal	O
-	O
weight	O
counterparts	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
without	O
sex	O
difference	O
.	O

Circulating	O
amylin	B-GP
was	O
positively	O
associated	O
with	O
CRP	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
BMI	O
,	O
waist	O
circumference	O
,	O
blood	O
pressure	O
,	O
fasting	O
glucose	O
,	O
insulin	B-GP
,	O
amylin	B-GP
/	O
insulin	B-GP
ratio	O
,	O
HOMA	O
-	O
IR	B-DS
,	O
LDL	O
cholesterol	O
and	O
triglycerides	O
,	O
while	O
negatively	O
associated	O
with	O
HDL	O
cholesterol	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
).	O

After	O
multiple	O
adjustments	O
,	O
the	O
risk	O
of	O
MetS	B-DS
was	O
significantly	O
higher	O
(	O
odds	O
ratio	O
3	O
.	O
71	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
2	O
.	O
53	O
to	O
5	O
.	O
46	O
)	O
comparing	O
the	O
highest	O
with	O
the	O
lowest	O
amylin	B-GP
quartile	O
.	O

The	O
association	O
remained	O
significant	O
even	O
further	O
controlling	O
for	O
BMI	O
,	O
inflammatory	O
markers	O
,	O
insulin	B-GP
or	O
HOMA	O
-	O
IR	B-DS
.	O

Conclusions	O

Our	O
study	O
suggests	O
that	O
amylin	B-GP
is	O
strongly	O
associated	O
with	O
inflammatory	O
markers	O
and	O
MetS	B-DS
.	O

The	O
amylin	B-GP
-	O
MetS	B-DS
association	O
is	O
independent	O
of	O
established	O
risk	O
factors	O
of	O
MetS	B-DS
,	O
including	O
obesity	B-DS
,	O
inflammatory	O
markers	O
and	O
insulin	B-DS
resistance	I-DS
.	O

The	O
causal	O
role	O
of	O
hyperamylinemia	O
in	O
the	O
development	O
of	O
MetS	B-DS
needs	O
to	O
be	O
confirmed	O
prospectively	O
.	O

Introduction	O

Amylin	B-GP
,	O
also	O
named	O
islet	B-GP
amyloid	I-GP
polypeptide	I-GP
(	O
IAPP	B-GP
),	O
is	O
a	O
37	O
amino	O
acid	O
polypeptide	O
initially	O
isolated	O
from	O
amyloid	O
deposit	O
in	O
pancreatic	O
islets	O
of	O
type	B-DS
2	I-DS
diabetes	I-DS
patients	O
[	O
1	O
],	O
[	O
2	O
].	O

Amylin	B-GP
is	O
co	O
-	O
secreted	O
with	O
insulin	B-GP
by	O
β	O
-	O
cells	O
in	O
response	O
to	O
stimulation	O
of	O
glucose	O
,	O
free	O
fatty	O
acids	O
and	O
food	O
intake	O
[	O
3	O
]–[	O
5	O
].	O

Amylin	B-GP
is	O
an	O
important	O
player	O
in	O
the	O
control	O
of	O
energy	O
balance	O
[	O
6	O
].	O

Amylin	B-GP
inhibits	O
food	O
intake	O
by	O
promoting	O
meal	O
-	O
ending	O
satiation	O
,	O
possibly	O
through	O
stimulation	O
of	O
its	O
receptor	O
in	O
the	O
area	O
postrema	O
[	O
7	O
].	O

The	O
nucleus	O
of	O
the	O
solitary	O
tract	O
and	O
the	O
lateral	O
parabrachial	O
nucleus	O
seem	O
to	O
be	O
also	O
involved	O
in	O
the	O
inhibitory	O
effect	O
of	O
amylin	B-GP
on	O
food	O
intake	O
[	O
6	O
].	O

Amylin	B-GP
increases	O
energy	O
expenditure	O
after	O
peripheral	O
and	O
central	O
administration	O
in	O
animals	B-OG
[	O
6	O
].	O

Chronic	O
infusion	O
of	O
amylin	B-GP
into	O
the	O
brain	O
reduces	O
body	O
weight	O
gain	O
and	O
adiposity	O
,	O
while	O
chronic	O
infusion	O
of	O
an	O
amylin	B-GP
receptor	I-GP
antagonist	O
into	O
the	O
brain	O
increases	O
body	O
adiposity	O
[	O
6	O
],	O
[	O
8	O
].	O

Amylin	B-GP
was	O
found	O
in	O
vitro	O
to	O
inhibit	O
both	O
basal	O
and	O
insulin	B-GP
stimulated	O
glycogenesis	O
in	O
rat	B-OG
skeleton	O
muscle	O
[	O
9	O
]	O
and	O
also	O
to	O
impair	O
glucose	O
disposal	O
in	O
liver	O
cells	O
[	O
10	O
].	O

Moreover	O
,	O
an	O
animal	B-OG
study	O
also	O
showed	O
that	O
amylin	B-GP
could	O
suppress	O
insulin	B-GP
secretion	O
by	O
enhancing	O
β	O
-	O
cell	O
apoptosis	O
,	O
which	O
consequently	O
induced	O
hepatic	O
and	O
extrahepatic	O
insulin	B-DS
resistance	I-DS
and	O
glucose	O
dysregulation	O
in	O
human	B-OG
IAPP	B-GP
transgenic	O
rats	B-OG
[	O
11	O
].	O

Infusion	O
of	O
amylin	B-GP
in	O
dog	B-OG
also	O
induced	O
peripheral	O
insulin	B-DS
resistance	I-DS
[	O
12	O
].	O

Elevated	O
levels	O
of	O
amylin	B-GP
were	O
observed	O
in	O
obese	O
children	O
[	O
13	O
]	O
and	O
obese	O
adults	O
with	O
impaired	B-DS
glucose	I-DS
tolerance	I-DS
or	O
type	B-DS
2	I-DS
diabetes	I-DS
[	O
14	O
],	O
or	O
in	O
women	O
with	O
polycystic	B-DS
ovary	I-DS
syndrome	I-DS
and	O
preterm	O
neonates	O
with	O
feed	O
intolerance	O
[	O
15	O
],	O
[	O
16	O
].	O

However	O
,	O
the	O
pathophysiological	O
role	O
(	O
s	O
)	O
of	O
amylin	B-GP
in	O
human	B-OG
metabolic	B-DS
diseases	I-DS
have	O
not	O
been	O
studied	O
in	O
large	O
-	O
scale	O
populations	O
.	O

Metabolic	B-DS
syndrome	I-DS
(	O
MetS	B-DS
),	O
an	O
aggregation	O
of	O
metabolic	O
abnormalities	O
comprising	O
central	B-DS
obesity	I-DS
,	O
dyslipidemia	B-DS
,	O
elevated	O
blood	O
pressure	O
and	O
hyperglycemia	B-DS
,	O
is	O
a	O
generally	O
acknowledged	O
precursor	O
of	O
type	B-DS
2	I-DS
diabetes	I-DS
and	O
cardiovascular	B-DS
disease	I-DS
(	O
CVD	B-DS
)	O
[	O
17	O
].	O

A	O
recent	O
meta	O
-	O
analysis	O
showed	O
that	O
MetS	B-DS
is	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
risk	O
of	O
CVD	B-DS
,	O
CVD	B-DS
mortality	O
,	O
and	O
stroke	B-DS
[	O
18	O
].	O

Owing	O
to	O
excess	O
caloric	O
intake	O
and	O
a	O
sedentary	O
lifestyle	O
,	O
global	O
epidemic	O
trends	O
of	O
obesity	B-DS
and	O
MetS	B-DS
have	O
become	O
one	O
of	O
the	O
public	O
health	O
challenges	O
not	O
only	O
in	O
Western	O
countries	O
[	O
19	O
]	O
but	O
also	O
in	O
Asian	O
societies	O
like	O
China	O
[	O
20	O
].	O

It	O
was	O
estimated	O
that	O
approximate	O
38	O
%	O
of	O
men	O
and	O
33	O
%	O
of	O
women	O
aged	O
35	O
–	O
74	O
years	O
in	O
China	O
had	O
at	O
least	O
one	O
component	O
of	O
MetS	B-DS
,	O
and	O
14	O
%	O
of	O
men	O
and	O
18	O
%	O
of	O
women	O
had	O
three	O
or	O
more	O
components	O
of	O
MetS	B-DS
[	O
20	O
].	O

During	O
past	O
decades	O
,	O
accumulating	O
evidence	O
has	O
highlighted	O
chronic	O
low	O
-	O
grade	O
inflammation	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
involving	O
in	O
pathogenesis	O
of	O
obesity	B-DS
and	O
related	O
metabolic	B-DS
disorders	I-DS
such	O
as	O
metabolic	B-DS
syndrome	I-DS
,	O
type	B-DS
2	I-DS
diabetes	I-DS
and	O
cardiovascular	B-DS
diseases	I-DS
[	O
21	O
].	O

However	O
,	O
evidence	O
is	O
scarce	O
about	O
the	O
relationships	O
between	O
amylin	B-GP
,	O
inflammatory	O
status	O
and	O
metabolic	B-DS
diseases	I-DS
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
distribution	O
of	O
plasma	O
amylin	B-GP
and	O
its	O
associations	O
with	O
inflammatory	O
markers	O
and	O
MetS	B-DS
in	O
1011	O
apparently	O
healthy	O
Chinese	O
adults	O
.	O

We	O
also	O
examined	O
whether	O
the	O
amylin	B-GP
-	O
MetS	B-DS
association	O
is	O
independent	O
of	O
well	O
established	O
risk	O
factors	O
including	O
obesity	B-DS
,	O
inflammatory	O
markers	O
and	O
insulin	B-DS
resistance	I-DS
.	O

Materials	O
and	O
Methods	O

Ethics	O
statements	O

The	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
Institute	O
for	O
Nutritional	O
Sciences	O
,	O
Chinese	O
Academy	O
of	O
Sciences	O
(	O
Permit	O
No	O
.	O

E	O
-	O
2007	O
-	O
01	O
)	O
and	O
a	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	O
.	O

Study	O
design	O

The	O
study	O
design	O
and	O
recruitment	O
of	O
participants	O
have	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
22	O
].	O

In	O
brief	O
,	O
the	O
study	O
population	O
was	O
from	O
the	O
Gut	O
Microbiota	B-OG
and	O
Obesity	B-DS
Study	O
,	O
a	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
among	O
noninstitutionalized	O
residents	O
aged	O
35	O
–	O
54	O
years	O
in	O
Shanghai	O
,	O
China	O
.	O

Two	O
urban	O
districts	O
(	O
Luwan	O
and	O
Zhabei	O
)	O
were	O
chosen	O
to	O
represent	O
people	O
with	O
high	O
and	O
low	O
socioeconomic	O
status	O
in	O
urban	O
Shanghai	O
.	O

Eligible	O
candidates	O
were	O
apparently	O
healthy	O
adults	O
who	O
have	O
lived	O
in	O
Shanghai	O
for	O
at	O
least	O
10	O
years	O
.	O

Five	O
hundred	O
pairs	O
of	O
age	O
-	O
and	O
sex	O
-	O
matched	O
subjects	O
(	O
overweight	O
/	O
obesity	B-DS
)	O
and	O
control	O
subjects	O
(	O
normal	O
-	O
weight	O
)	O
were	O
planned	O
to	O
be	O
recruited	O
.	O

Finally	O
,	O
a	O
total	O
of	O
1	O
,	O
059	O
eligible	O
participants	O
were	O
successfully	O
recruited	O
from	O
November	O
2007	O
to	O
January	O
2008	O
.	O

Normal	O
weight	O
and	O
overweight	O
/	O
obesity	B-DS
were	O
defined	O
as	O
18	O
≤	O
BMI	O
<	O
24	O
.	O
0	O
kg	O
/	O
m2	O
and	O
BMI	O
≥	O
24	O
.	O
0	O
kg	O
/	O
m2	O
,	O
respectively	O
,	O
according	O
to	O
the	O
recommendation	O
by	O
the	O
Working	O
Group	O
on	O
Obesity	B-DS
in	O
China	O
[	O
23	O
]–[	O
25	O
].	O

The	O
BMI	O
range	O
is	O
18	O
.	O
0	O
to	O
23	O
.	O
9	O
kg	O
/	O
m2	O
for	O
normal	O
weight	O
and	O
24	O
.	O
0	O
to	O
40	O
.	O
5	O
kg	O
/	O
m2	O
for	O
overweight	O
/	O
obesity	B-DS
.	O

Face	O
to	O
face	O
interviews	O
were	O
conducted	O
by	O
trained	O
physicians	O
or	O
public	O
health	O
workers	O
from	O
the	O
local	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
and	O
also	O
from	O
community	O
clinics	O
.	O

Information	O
of	O
demographic	O
variables	O
,	O
health	O
status	O
and	O
behaviors	O
,	O
physical	O
activity	O
and	O
educational	O
attainment	O
were	O
obtained	O
through	O
a	O
standardized	O
questionnaire	O
.	O

Family	O
history	O
of	O
chronic	B-DS
diseases	I-DS
was	O
positive	O
if	O
one	O
of	O
the	O
parents	O
or	O
siblings	O
had	O
coronary	B-DS
heart	I-DS
disease	I-DS
,	O
stroke	B-DS
,	O
or	O
type	B-DS
2	I-DS
diabetes	I-DS
.	O

Body	O
weight	O
,	O
height	O
,	O
waist	O
circumference	O
,	O
and	O
blood	O
pressure	O
were	O
measured	O
using	O
a	O
standardized	O
protocol	O
[	O
22	O
].	O

Laboratory	O
measurements	O

Overnight	O
fasting	O
venous	O
blood	O
samples	O
were	O
collected	O
by	O
tubes	O
containing	O
EDTA	O
,	O
centrifuged	O
at	O
4	O
°	O
C	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
laboratory	O
analyses	O
.	O

Laboratory	O
assays	O
for	O
total	O
cholesterol	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
,	O
triglycerides	O
,	O
glucose	O
,	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
(	O
CRP	B-GP
),	O
interleukin	B-GP
6	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
),	O
and	O
insulin	B-GP
were	O
described	O
previously	O
[	O
22	O
].	O

The	O
insulin	B-DS
resistance	I-DS
index	O
(	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-DS
resistance	I-DS
,	O
HOMA	O
-	O
IR	B-DS
)	O
was	O
calculated	O
according	O
to	O
updated	O
homeostasis	O
model	O
assessment	O
methods	O
(	O
http	O
://	O
www	O
.	O
dtu	O
.	O
ox	O
.	O
ac	O
.	O
uk	O
/).	O

Amylin	B-GP
concentrations	O
were	O
measured	O
by	O
a	O
monoclonal	O
antibody	O
-	O
based	O
sandwich	O
immunoassay	O
(	O
Human	B-OG
amylin	B-GP
total	O
ELISA	O
kit	O
,	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
).	O

The	O
assay	O
has	O
a	O
sensitivity	O
of	O
1	O
pmol	O
/	O
l	O
with	O
measurable	O
concentrations	O
within	O
1	O
–	O
100	O
pmol	O
/	O
l	O
.	O

All	O
procedures	O
followed	O
the	O
manufacture	O
'	O
s	O
instructions	O
with	O
two	O
quality	O
controls	O
in	O
expected	O
ranges	O
for	O
each	O
assay	O
.	O

The	O
inter	O
assay	O
-	O
CV	O
was	O
10	O
%	O
for	O
one	O
of	O
quality	O
controls	O
and	O
was	O
7	O
.	O
3	O
%	O
for	O
the	O
other	O
one	O
.	O

Every	O
tenth	O
sample	O
was	O
duplicated	O
on	O
the	O
same	O
plate	O
and	O
the	O
average	O
intra	O
-	O
assay	O
CV	O
for	O
amylin	B-GP
was	O
7	O
.	O
6	O
%.	O

Forty	O
-	O
eight	O
persons	O
with	O
limited	O
plasma	O
samples	O
were	O
excluded	O
and	O
data	O
from	O
1011	O
(	O
527	O
overweight	O
/	O
obese	O
and	O
484	O
normal	O
-	O
weight	O
)	O
participants	O
were	O
available	O
for	O
amylin	B-GP
analyses	O
.	O

Definition	O
of	O
Mets	B-DS

MetS	B-DS
was	O
defined	O
based	O
on	O
the	O
updated	O
National	O
Cholesterol	O
Education	O
Program	O
Adult	O
Treatment	O
Panel	O
III	O
criteria	O
for	O
Asian	O
-	O
Americans	O
[	O
17	O
],	O
including	O
at	O
least	O
three	O
of	O
the	O
following	O
components	O
:	O
1	O
)	O
waist	O
circumference	O
≥	O
90	O
cm	O
in	O
men	O
or	O
≥	O
80	O
cm	O
in	O
women	O
;	O
2	O
)	O
triglycerides	O
≥	O
1	O
.	O
7	O
mmol	O
/	O
l	O
;	O
3	O
)	O
HDL	O
cholesterol	O
<	O
1	O
.	O
03	O
mmol	O
/	O
l	O
in	O
men	O
,	O
or	O
<	O
1	O
.	O
30	O
mmol	O
/	O
l	O
in	O
women	O
;	O
4	O
)	O
blood	O
pressure	O
≥	O
130	O
/	O
85	O
mm	O
Hg	O
,	O
or	O
current	O
use	O
of	O
antihypertensive	O
medications	O
;	O
and	O
5	O
)	O
fasting	O
plasma	O
glucose	O
≥	O
5	O
.	O
6	O
mmol	O
/	O
l	O
.	O

Statistical	O
analyses	O

Normally	O
distributed	O
variables	O
were	O
expressed	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
),	O
while	O
variables	O
with	O
a	O
skewed	O
distribution	O
,	O
including	O
amylin	B-GP
,	O
insulin	B-GP
,	O
HOMA	O
-	O
IR	B-DS
,	O
amylin	B-GP
/	O
insulin	B-GP
ratio	O
,	O
triglycerides	O
,	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
,	O
were	O
reported	O
as	O
geometric	O
mean	O
(	O
95	O
%	O
confidence	O
interval	O
).	O

Amylin	B-GP
was	O
log	O
transformed	O
to	O
approximate	O
normality	O
before	O
statistical	O
analyses	O
.	O

Categorical	O
variables	O
were	O
represented	O
by	O
frequency	O
and	O
percentage	O
.	O

Analysis	O
of	O
covariance	O
was	O
used	O
to	O
calculate	O
amylin	B-GP
concentrations	O
according	O
to	O
sex	O
,	O
age	O
and	O
BMI	O
.	O

Continuous	O
characteristics	O
across	O
amylin	B-GP
quartiles	O
were	O
compared	O
using	O
analysis	O
of	O
covariance	O
,	O
whereas	O
categorical	O
characteristics	O
across	O
amylin	B-GP
quartiles	O
were	O
compared	O
using	O
logistic	O
regression	O
model	O
.	O

Medians	O
of	O
each	O
amylin	B-GP
quartile	O
were	O
included	O
as	O
an	O
independent	O
variable	O
for	O
trend	O
test	O
.	O

Spearman	O
partial	O
correlation	O
coefficients	O
of	O
amylin	B-GP
with	O
metabolic	O
parameters	O
and	O
inflammatory	O
markers	O
were	O
calculated	O
in	O
the	O
whole	O
sample	O
and	O
subgroups	O
.	O

Multivariate	O
logistic	O
regression	O
models	O
were	O
applied	O
to	O
evaluate	O
the	O
adjusted	O
odds	O
ratios	O
(	O
ORs	O
)	O
for	O
MetS	B-DS
and	O
its	O
components	O
according	O
to	O
the	O
amylin	B-GP
quartiles	O
.	O

Potential	O
confounders	O
were	O
carefully	O
controlled	O
,	O
including	O
age	O
,	O
sex	O
,	O
lifestyle	O
factors	O
,	O
educational	O
attainment	O
,	O
family	O
history	O
of	O
chronic	B-DS
diseases	I-DS
,	O
and	O
inflammatory	O
markers	O
.	O

Potential	O
interactions	O
between	O
BMI	O
,	O
inflammatory	O
markers	O
,	O
insulin	B-GP
,	O
HOMA	O
-	O
IR	B-DS
and	O
amylin	B-GP
were	O
also	O
examined	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
with	O
Stata	O
9	O
.	O
2	O
.	O

(	O
College	O
Station	O
,	O
TX	O
,	O
USA	O
)	O
and	O
considered	O
statistically	O
significant	O
when	O
2	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
.	O

Results	O

Distribution	O
of	O
amylin	B-GP
concentrations	O
and	O
characteristics	O
of	O
participants	O

As	O
shown	O
in	O
Table	O
1	O
,	O
geometric	O
means	O
of	O
amylin	B-GP
were	O
significantly	O
higher	O
in	O
older	O
(	O
aged	O
≥	O
45	O
years	O
)	O
and	O
overweight	O
/	O
obese	O
participants	O
than	O
their	O
younger	O
(	O
6	O
.	O
85	O
vs	O
.	O
6	O
.	O
57	O
pmol	O
/	O
l	O
,	O
P	O
=	O
0	O
.	O
030	O
)	O
and	O
normal	O
weight	O
counterparts	O
(	O
7	O
.	O
01	O
vs	O
.	O
6	O
.	O
46	O
pmol	O
/	O
l	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

When	O
participants	O
were	O
characterized	O
according	O
to	O
amylin	B-GP
quartiles	O
(	O
Table	O
2	O
),	O
persons	O
in	O
the	O
higher	O
amylin	B-GP
quartile	O
had	O
significantly	O
higher	O
levels	O
of	O
BMI	O
,	O
waist	O
circumference	O
,	O
blood	O
pressure	O
,	O
fasting	O
glucose	O
,	O
insulin	B-GP
,	O
HOMA	O
-	O
IR	B-DS
,	O
amylin	B-GP
/	O
insulin	B-GP
ratio	O
,	O
total	O
and	O
LDL	O
cholesterol	O
,	O
triglycerides	O
,	O
but	O
lower	O
HDL	O
cholesterol	O
concentrations	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
those	O
in	O
the	O
lower	O
quartile	O
.	O

Moreover	O
,	O
plasma	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
also	O
elevated	O
along	O
with	O
increased	O
amylin	B-GP
quartiles	O
(	O
both	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
also	O
characterized	O
the	O
participants	O
according	O
to	O
BMI	O
quartiles	O
,	O
and	O
found	O
that	O
plasma	O
amylin	B-GP
concentrations	O
increased	O
gradually	O
according	O
to	O
the	O
quartile	O
of	O
BMI	O
,	O
the	O
geometric	O
means	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
])	O
is	O
6	O
.	O
21	O
(	O
5	O
.	O
99	O
–	O
6	O
.	O
44	O
),	O
6	O
.	O
65	O
(	O
6	O
.	O
40	O
–	O
6	O
.	O
90	O
),	O
6	O
.	O
84	O
(	O
6	O
.	O
59	O
–	O
7	O
.	O
10	O
)	O
and	O
7	O
.	O
20	O
(	O
6	O
.	O
96	O
–	O
7	O
.	O
46	O
)	O
pmol	O
/	O
l	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
for	O
trend	O
).	O

Amylin	B-GP
concentrations	O
according	O
to	O
sex	O
,	O
age	O
and	O
obesity	B-DS
status	O
(	O
pmol	O
/	O
l	O
)	O
a	O
.	O

n	O

Geometric	O
mean	O
(	O
95	O
%	O
confidence	O
interval	O
)	O

P	O
value	O

Sexb	O

0	O
.	O
121	O

Male	O

370	O

6	O
.	O
85	O
(	O
6	O
.	O
64	O
–	O
7	O
.	O
06	O
)	O

Female	O

641	O

6	O
.	O
64	O
(	O
6	O
.	O
49	O
–	O
6	O
.	O
80	O
)	O

Agec	O

0	O
.	O
030	O

<	O
45	O
years	O

395	O

6	O
.	O
57	O
(	O
6	O
.	O
38	O
–	O
6	O
.	O
77	O
)	O

≥	O
45	O
years	O

616	O

6	O
.	O
85	O
(	O
6	O
.	O
69	O
–	O
7	O
.	O
02	O
)	O

Obesity	B-DS
statusd	O

<	O
0	O
.	O
001	O

Normal	O
weight	O

484	O

6	O
.	O
46	O
(	O
6	O
.	O
29	O
–	O
6	O
.	O
64	O
)	O

Overweight	O
/	O
Obese	O

527	O

7	O
.	O
01	O
(	O
6	O
.	O
83	O
–	O
7	O
.	O
19	O
)	O

Geometric	O
means	O
of	O
amylin	B-GP
concentrations	O
were	O
compared	O
using	O
general	O
linear	O
models	O
(	O
n	O
=	O
1011	O
).	O

Adjustment	O
for	O
BMI	O
and	O
age	O
.	O

Adjustment	O
for	O
sex	O
and	O
BMI	O
.	O

Adjustment	O
for	O
age	O
and	O
sex	O
.	O

Characteristics	O
of	O
participants	O
according	O
to	O
amylin	B-GP
quartiles	O
(	O
n	O
=	O
1011	O
)	O
a	O
.	O

Variables	O

Q1	O

Q2	O

Q3	O

Q4	O

P	O
for	O
trend	O

n	O
(	O
case	O
/	O
control	O
)	O

252	O
(	O
101	O
/	O
151	O
)	O

253	O
(	O
129	O
/	O
124	O
)	O

253	O
(	O
132	O
/	O
121	O
)	O

253	O
(	O
165	O
/	O
88	O
)	O

Amylin	B-GP
(	O
pmol	O
/	O
l	O
)	O

4	O
.	O
71	O
(	O
4	O
.	O
61	O
–	O
4	O
.	O
82	O
)	O

6	O
.	O
24	O
(	O
6	O
.	O
20	O
–	O
6	O
.	O
27	O
)	O

7	O
.	O
21	O
(	O
7	O
.	O
18	O
–	O
7	O
.	O
25	O
)	O

9	O
.	O
59	O
(	O
9	O
.	O
28	O
–	O
9	O
.	O
90	O
)	O

<	O
0	O
.	O
001	O

Age	O
(	O
years	O
)	O
b	O

45	O
.	O
2	O
(	O
5	O
.	O
5	O
)	O

45	O
.	O
5	O
(	O
5	O
.	O
5	O
)	O

46	O
.	O
0	O
(	O
5	O
.	O
5	O
)	O

46	O
.	O
8	O
(	O
5	O
.	O
1	O
)	O

<	O
0	O
.	O
001	O

Male	O
,	O
n	O
(%)	O
b	O

94	O
(	O
37	O
.	O
3	O
)	O

83	O
(	O
32	O
.	O
8	O
)	O

88	O
(	O
34	O
.	O
8	O
)	O

105	O
(	O
41	O
.	O
5	O
)	O

0	O
.	O
242	O

Education	O
,	O
n	O
(%)	O

0	O
.	O
994	O

0	O
–	O
9	O
years	O

68	O
(	O
27	O
.	O
0	O
)	O

67	O
(	O
26	O
.	O
5	O
)	O

73	O
(	O
28	O
.	O
9	O
)	O

68	O
(	O
26	O
.	O
9	O
)	O

10	O
–	O
12	O
years	O

129	O
(	O
51	O
.	O
2	O
)	O

129	O
(	O
51	O
.	O
0	O
)	O

129	O
(	O
51	O
.	O
0	O
)	O

137	O
(	O
54	O
.	O
2	O
)	O

≥	O
13	O
years	O

55	O
(	O
21	O
.	O
8	O
)	O

57	O
(	O
22	O
.	O
5	O
)	O

51	O
(	O
20	O
.	O
2	O
)	O

48	O
(	O
19	O
.	O
0	O
)	O

Current	O
smoker	O
,	O
n	O
(%)	O

59	O
(	O
23	O
.	O
4	O
)	O

54	O
(	O
21	O
.	O
3	O
)	O

57	O
(	O
22	O
.	O
5	O
)	O

74	O
(	O
29	O
.	O
3	O
)	O

0	O
.	O
271	O

Alcohol	O
drinker	O
,	O
n	O
(%)	O

111	O
(	O
44	O
.	O
1	O
)	O

74	O
(	O
29	O
.	O
3	O
)	O

83	O
(	O
32	O
.	O
8	O
)	O

96	O
(	O
37	O
.	O
9	O
)	O

0	O
.	O
083	O

Physical	O
activity	O
,	O
n	O
(%)	O

0	O
.	O
471	O

Low	O

13	O
(	O
5	O
.	O
2	O
)	O

28	O
(	O
11	O
.	O
1	O
)	O

23	O
(	O
9	O
.	O
1	O
)	O

32	O
(	O
12	O
.	O
7	O
)	O

Moderate	O

158	O
(	O
62	O
.	O
7	O
)	O

147	O
(	O
58	O
.	O
1	O
)	O

145	O
(	O
57	O
.	O
3	O
)	O

136	O
(	O
53	O
.	O
8	O
)	O

High	O

81	O
(	O
32	O
.	O
1	O
)	O

78	O
(	O
30	O
.	O
8	O
)	O

85	O
(	O
33	O
.	O
6	O
)	O

85	O
(	O
33	O
.	O
6	O
)	O

Family	O
history	O
of	O
coronary	B-DS
heart	I-DS
disease	I-DS
,	O
stroke	B-DS
and	O
diabetes	B-DS
,	O
n	O
(%)	O

103	O
(	O
40	O
.	O
9	O
)	O

98	O
(	O
38	O
.	O
7	O
)	O

101	O
(	O
39	O
.	O
9	O
)	O

101	O
(	O
39	O
.	O
9	O
)	O

0	O
.	O
693	O

Metabolic	B-DS
syndrome	I-DS
,	O
n	O
(%)	O

65	O
(	O
25	O
.	O
8	O
)	O

83	O
(	O
32	O
.	O
8	O
)	O

119	O
(	O
47	O
.	O
0	O
)	O

145	O
(	O
57	O
.	O
3	O
)	O

<	O
0	O
.	O
001	O

BMI	O
(	O
kg	O
/	O
m2	O
)	O

23	O
.	O
4	O
(	O
3	O
.	O
7	O
)	O

24	O
.	O
2	O
(	O
3	O
.	O
8	O
)	O

24	O
.	O
9	O
(	O
4	O
.	O
2	O
)	O

25	O
.	O
8	O
(	O
4	O
.	O
1	O
)	O

<	O
0	O
.	O
001	O

Waist	O
circumference	O
(	O
cm	O
)	O

81	O
.	O
5	O
(	O
10	O
.	O
5	O
)	O

82	O
.	O
9	O
(	O
10	O
.	O
3	O
)	O

85	O
.	O
3	O
(	O
11	O
.	O
1	O
)	O

89	O
.	O
0	O
(	O
11	O
.	O
2	O
)	O

<	O
0	O
.	O
001	O

SBP	O
(	O
mm	O
Hg	O
)	O

121	O
.	O
7	O
(	O
15	O
.	O
5	O
)	O

122	O
.	O
1	O
(	O
16	O
.	O
0	O
)	O

126	O
.	O
7	O
(	O
18	O
.	O
9	O
)	O

128	O
.	O
1	O
(	O
18	O
.	O
7	O
)	O

<	O
0	O
.	O
001	O

DBP	O
(	O
mm	O
Hg	O
)	O

76	O
.	O
9	O
(	O
10	O
.	O
9	O
)	O

78	O
.	O
2	O
(	O
11	O
.	O
3	O
)	O

80	O
.	O
5	O
(	O
12	O
.	O
0	O
)	O

81	O
.	O
7	O
(	O
11	O
.	O
6	O
)	O

<	O
0	O
.	O
001	O

Fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O

5	O
.	O
8	O
(	O
1	O
.	O
0	O
)	O

6	O
.	O
0	O
(	O
1	O
.	O
5	O
)	O

6	O
.	O
1	O
(	O
1	O
.	O
3	O
)	O

6	O
.	O
3	O
(	O
1	O
.	O
4	O
)	O

<	O
0	O
.	O
001	O

Insulin	B-GP
(	O
µU	O
/	O
ml	O
)	O

7	O
.	O
46	O
(	O
7	O
.	O
03	O
–	O
7	O
.	O
92	O
)	O

8	O
.	O
43	O
(	O
7	O
.	O
88	O
–	O
9	O
.	O
01	O
)	O

9	O
.	O
52	O
(	O
8	O
.	O
97	O
–	O
10	O
.	O
11	O
)	O

11	O
.	O
80	O
(	O
11	O
.	O
05	O
–	O
12	O
.	O
61	O
)	O

<	O
0	O
.	O
001	O

HOMA	O
-	O
IR	B-DS

0	O
.	O
87	O
(	O
0	O
.	O
82	O
–	O
0	O
.	O
92	O
)	O

0	O
.	O
98	O
(	O
0	O
.	O
92	O
–	O
1	O
.	O
05	O
)	O

1	O
.	O
11	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
18	O
)	O

1	O
.	O
38	O
(	O
1	O
.	O
29	O
–	O
1	O
.	O
48	O
)	O

<	O
0	O
.	O
001	O

Amylin	B-GP
/	O
insulin	B-GP

0	O
.	O
09	O
(	O
0	O
.	O
09	O
–	O
0	O
.	O
10	O
)	O

0	O
.	O
11	O
(	O
0	O
.	O
10	O
–	O
0	O
.	O
11	O
)	O

0	O
.	O
11	O
(	O
0	O
.	O
10	O
–	O
0	O
.	O
12	O
)	O

0	O
.	O
12	O
(	O
0	O
.	O
11	O
–	O
0	O
.	O
13	O
)	O

<	O
0	O
.	O
001	O

Total	O
cholesterol	O
(	O
mmol	O
/	O
l	O
)	O

5	O
.	O
0	O
(	O
1	O
.	O
0	O
)	O

5	O
.	O
1	O
(	O
1	O
.	O
2	O
)	O

5	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O

5	O
.	O
4	O
(	O
1	O
.	O
1	O
)	O

<	O
0	O
.	O
001	O

LDL	O
cholesterol	O
(	O
mmol	O
/	O
l	O
)	O

3	O
.	O
1	O
(	O
0	O
.	O
8	O
)	O

3	O
.	O
2	O
(	O
1	O
.	O
0	O
)	O

3	O
.	O
4	O
(	O
1	O
.	O
0	O
)	O

3	O
.	O
4	O
(	O
0	O
.	O
9	O
)	O

<	O
0	O
.	O
001	O

HDL	O
cholesterol	O
(	O
mmol	O
/	O
l	O
)	O

1	O
.	O
5	O
(	O
0	O
.	O
4	O
)	O

1	O
.	O
4	O
(	O
0	O
.	O
4	O
)	O

1	O
.	O
4	O
(	O
0	O
.	O
4	O
)	O

1	O
.	O
3	O
(	O
0	O
.	O
4	O
)	O

<	O
0	O
.	O
001	O

Triglycerides	O
(	O
mmol	O
/	O
l	O
)	O

1	O
.	O
01	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
07	O
)	O

1	O
.	O
10	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
18	O
)	O

1	O
.	O
36	O
(	O
1	O
.	O
26	O
–	O
1	O
.	O
46	O
)	O

1	O
.	O
70	O
(	O
1	O
.	O
57	O
–	O
1	O
.	O
84	O
)	O

<	O
0	O
.	O
001	O

CRP	B-GP
(	O
mg	O
/	O
l	O
)	O

0	O
.	O
74	O
(	O
0	O
.	O
66	O
–	O
0	O
.	O
82	O
)	O

0	O
.	O
83	O
(	O
0	O
.	O
74	O
–	O
0	O
.	O
94	O
)	O

1	O
.	O
00	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
13	O
)	O

1	O
.	O
17	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
31	O
)	O

<	O
0	O
.	O
001	O

IL	B-GP
-	I-GP
6	I-GP
(	O
pg	O
/	O
ml	O
)	O

1	O
.	O
33	O
(	O
1	O
.	O
23	O
–	O
1	O
.	O
43	O
)	O

1	O
.	O
27	O
(	O
1	O
.	O
17	O
–	O
1	O
.	O
37	O
)	O

1	O
.	O
45	O
(	O
1	O
.	O
34	O
–	O
1	O
.	O
56	O
)	O

1	O
.	O
63	O
(	O
1	O
.	O
50	O
–	O
1	O
.	O
76	O
)	O

<	O
0	O
.	O
001	O

Data	O
are	O
arithmetic	O
mean	O
(	O
SD	O
)	O
or	O
geometric	O
mean	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
if	O
not	O
specified	O
.	O

Percentages	O
may	O
not	O
sum	O
to	O
100	O
because	O
of	O
rounding	O
.	O
P	O
for	O
trend	O
was	O
calculated	O
after	O
adjustment	O
for	O
age	O
and	O
sex	O
.	O

Not	O
adjusted	O
for	O
itself	O
.	O

Correlations	O
of	O
amylin	B-GP
concentrations	O
with	O
metabolic	O
parameters	O
and	O
inflammatory	O
markers	O

Amylin	B-GP
was	O
positively	O
correlated	O
with	O
BMI	O
,	O
waist	O
circumference	O
,	O
blood	O
pressure	O
,	O
fasting	O
glucose	O
,	O
insulin	B-GP
,	O
HOMA	O
-	O
IR	B-DS
,	O
total	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
,	O
triglycerides	O
,	O
inflammatory	O
markers	O
of	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
,	O
while	O
,	O
negatively	O
correlated	O
with	O
plasma	O
HDL	O
-	O
cholesterol	O
(	O
Table	O
3	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
),	O
after	O
adjustment	O
for	O
age	O
and	O
sex	O
.	O

Among	O
all	O
the	O
metabolic	O
parameters	O
,	O
amylin	B-GP
showed	O
the	O
strongest	O
correlation	O
with	O
insulin	B-GP
and	O
HOMA	O
-	O
IR	B-DS
.	O

In	O
stratified	O
analyses	O
,	O
the	O
correlations	O
were	O
generally	O
stronger	O
in	O
overweight	O
/	O
obese	O
and	O
male	O
participants	O
than	O
in	O
their	O
normal	O
-	O
weight	O
and	O
female	O
peers	O
.	O

Partial	O
spearman	O
correlation	O
coefficients	O
of	O
amylin	B-GP
with	O
metabolic	O
parameters	O
and	O
inflammatory	O
markers	O
.	O

Totala	O
(	O
n	O
=	O
1011	O
)	O

Normal	O
weighta	O
(	O
n	O
=	O
484	O
)	O

Overweight	O
/	O
obesea	O
(	O
n	O
=	O
527	O
)	O

Maleb	O
(	O
n	O
=	O
370	O
)	O

Femaleb	O
(	O
n	O
=	O
641	O
)	O

r	O

P	O
value	O

r	O

P	O
value	O

r	O

P	O
value	O

r	O

P	O
value	O

r	O

P	O
value	O

BMI	O

0	O
.	O
21	O

<	O
0	O
.	O
001	O

0	O
.	O
12	O

0	O
.	O
007	O

0	O
.	O
18	O

<	O
0	O
.	O
001	O

0	O
.	O
29	O

<	O
0	O
.	O
001	O

0	O
.	O
17	O

<	O
0	O
.	O
001	O

Waist	O
circumference	O

0	O
.	O
24	O

<	O
0	O
.	O
001	O

0	O
.	O
18	O

<	O
0	O
.	O
001	O

0	O
.	O
20	O

<	O
0	O
.	O
001	O

0	O
.	O
34	O

<	O
0	O
.	O
001	O

0	O
.	O
18	O

<	O
0	O
.	O
001	O

SBP	O

0	O
.	O
13	O

<	O
0	O
.	O
001	O

0	O
.	O
05	O

0	O
.	O
229	O

0	O
.	O
08	O

0	O
.	O
062	O

0	O
.	O
19	O

<	O
0	O
.	O
001	O

0	O
.	O
08	O

0	O
.	O
044	O

DBP	O

0	O
.	O
14	O

<	O
0	O
.	O
001	O

0	O
.	O
07	O

0	O
.	O
131	O

0	O
.	O
09	O

0	O
.	O
042	O

0	O
.	O
19	O

<	O
0	O
.	O
001	O

0	O
.	O
11	O

0	O
.	O
007	O

Fasting	O
glucose	O

0	O
.	O
15	O

<	O
0	O
.	O
001	O

0	O
.	O
10	O

0	O
.	O
027	O

0	O
.	O
16	O

<	O
0	O
.	O
001	O

0	O
.	O
17	O

0	O
.	O
001	O

0	O
.	O
14	O

<	O
0	O
.	O
001	O

Insulin	B-GP

0	O
.	O
33	O

<	O
0	O
.	O
001	O

0	O
.	O
20	O

<	O
0	O
.	O
001	O

0	O
.	O
38	O

<	O
0	O
.	O
001	O

0	O
.	O
39	O

<	O
0	O
.	O
001	O

0	O
.	O
28	O

<	O
0	O
.	O
001	O

HOMA	O
-	O
IR	B-DS

0	O
.	O
33	O

<	O
0	O
.	O
001	O

0	O
.	O
21	O

<	O
0	O
.	O
001	O

0	O
.	O
38	O

<	O
0	O
.	O
001	O

0	O
.	O
40	O

<	O
0	O
.	O
001	O

0	O
.	O
29	O

<	O
0	O
.	O
001	O

Total	O
cholesterol	O

0	O
.	O
12	O

<	O
0	O
.	O
001	O

0	O
.	O
07	O

0	O
.	O
108	O

0	O
.	O
13	O

0	O
.	O
004	O

0	O
.	O
18	O

<	O
0	O
.	O
001	O

0	O
.	O
06	O

0	O
.	O
159	O

LDL	O
-	O
cholesterol	O

0	O
.	O
12	O

<	O
0	O
.	O
001	O

0	O
.	O
09	O

0	O
.	O
040	O

0	O
.	O
10	O

0	O
.	O
027	O

0	O
.	O
16	O

0	O
.	O
002	O

0	O
.	O
08	O

0	O
.	O
045	O

HDL	O
-	O
cholesterol	O

−	O
0	O
.	O
18	O

<	O
0	O
.	O
001	O

−	O
0	O
.	O
08	O

0	O
.	O
080	O

−	O
0	O
.	O
18	O

<	O
0	O
.	O
001	O

−	O
0	O
.	O
25	O

<	O
0	O
.	O
001	O

−	O
0	O
.	O
13	O

0	O
.	O
001	O

Triglycerides	O

0	O
.	O
31	O

<	O
0	O
.	O
001	O

0	O
.	O
17	O

<	O
0	O
.	O
001	O

0	O
.	O
35	O

<	O
0	O
.	O
001	O

0	O
.	O
39	O

<	O
0	O
.	O
001	O

0	O
.	O
24	O

<	O
0	O
.	O
001	O

CRP	B-GP

0	O
.	O
18	O

<	O
0	O
.	O
001	O

0	O
.	O
10	O

0	O
.	O
027	O

0	O
.	O
14	O

0	O
.	O
002	O

0	O
.	O
19	O

<	O
0	O
.	O
001	O

0	O
.	O
16	O

<	O
0	O
.	O
001	O

IL	B-GP
-	I-GP
6	I-GP

0	O
.	O
11	O

<	O
0	O
.	O
001	O

0	O
.	O
06	O

0	O
.	O
159	O

0	O
.	O
08	O

0	O
.	O
054	O

0	O
.	O
11	O

0	O
.	O
034	O

0	O
.	O
11	O

0	O
.	O
006	O

Correlation	O
coefficients	O
were	O
calculated	O
after	O
adjustment	O
for	O
age	O
and	O
sex	O
.	O

Correlation	O
coefficients	O
were	O
calculated	O
after	O
adjustment	O
for	O
age	O
only	O
.	O

Associations	O
of	O
amylin	B-GP
with	O
metabolic	B-DS
syndrome	I-DS
and	O
its	O
components	O

The	O
prevalence	O
of	O
MetS	B-DS
progressively	O
increased	O
from	O
25	O
.	O
8	O
%	O
to	O
57	O
.	O
3	O
%	O
across	O
amylin	B-GP
quartiles	O
(	O
Table	O
4	O
).	O

The	O
severity	O
of	O
MetS	B-DS
,	O
indicated	O
as	O
≤	O
1	O
,	O
2	O
,	O
3	O
and	O
≥	O
4	O
components	O
,	O
also	O
increased	O
gradually	O
across	O
amylin	B-GP
quartiles	O
(	O
Figure	O
1	O
).	O
Table	O
4	O
(	O
model	O
2	O
)	O
showed	O
that	O
,	O
compared	O
with	O
the	O
lowest	O
quartile	O
of	O
amylin	B-GP
,	O
the	O
ORs	O
in	O
the	O
highest	O
quartile	O
were	O
3	O
.	O
71	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
53	O
–	O
5	O
.	O
46	O
)	O
for	O
MetS	B-DS
,	O
2	O
.	O
72	O
(	O
1	O
.	O
88	O
–	O
3	O
.	O
93	O
)	O
for	O
central	B-DS
obesity	I-DS
,	O
1	O
.	O
66	O
(	O
1	O
.	O
14	O
–	O
2	O
.	O
41	O
)	O
for	O
elevated	O
blood	O
pressure	O
,	O
1	O
.	O
88	O
(	O
1	O
.	O
28	O
–	O
2	O
.	O
76	O
)	O
for	O
hyperglycemia	B-DS
,	O
5	O
.	O
55	O
(	O
3	O
.	O
58	O
–	O
8	O
.	O
61	O
)	O
for	O
hypertriglyceridemia	B-DS
,	O
and	O
2	O
.	O
56	O
(	O
1	O
.	O
75	O
–	O
3	O
.	O
76	O
)	O
for	O
low	O
HDL	O
cholesterol	O
(	O
P	O
<	O
0	O
.	O
001	O
for	O
trend	O
for	O
the	O
overall	O
risk	O
of	O
MetS	B-DS
and	O
most	O
of	O
the	O
features	O
except	O
elevated	O
blood	O
pressure	O
with	O
P	O
for	O
trend	O
=	O
0	O
.	O
002	O
).	O

Further	O
adjustment	O
for	O
BMI	O
and	O
inflammatory	O
markers	O
(	O
model	O
4	O
)	O
only	O
slightly	O
reduced	O
the	O
magnitude	O
of	O
the	O
association	O
of	O
amylin	B-GP
with	O
MetS	B-DS
(	O
with	O
an	O
OR	O
of	O
2	O
.	O
41	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
46	O
–	O
3	O
.	O
97	O
).	O

Although	O
further	O
adjustment	O
of	O
insulin	B-GP
based	O
on	O
model	O
2	O
decrease	O
the	O
magnitude	O
of	O
the	O
amylin	B-GP
-	O
MetS	B-DS
association	O
(	O
with	O
an	O
OR	O
of	O
1	O
.	O
85	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
21	O
–	O
2	O
.	O
85	O
),	O
the	O
association	O
of	O
amylin	B-GP
with	O
MetS	B-DS
is	O
still	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
001	O
for	O
trend	O
).	O

These	O
results	O
suggest	O
that	O
amylin	B-GP
is	O
associated	O
with	O
MetS	B-DS
independent	O
of	O
obesity	B-DS
,	O
inflammatory	O
markers	O
or	O
insulin	B-GP
.	O

The	O
severity	O
of	O
MetS	B-DS
according	O
to	O
amylin	B-GP
quartiles	O
.	O

P	O
<	O
0	O
.	O
001	O
for	O
trend	O
.	O

Odds	O
ratios	O
and	O
95	O
%	O
confidence	O
interval	O
for	O
MetS	B-DS
and	O
its	O
individual	O
components	O
according	O
to	O
amylin	B-GP
quartiles	O
(	O
n	O
=	O
1011	O
).	O

Odds	O
Ratios	O
(	O
95	O
%	O
CI	O
)	O

Q1	O
(<	O
5	O
.	O
70	O
)	O

Q2	O
(	O
5	O
.	O
70	O
–	O
6	O
.	O
75	O
)	O

Q3	O
(	O
6	O
.	O
75	O
–	O
7	O
.	O
83	O
)	O

Q4	O
(≥	O
7	O
.	O
83	O
)	O

P	O
for	O
trend	O

Metabolic	B-DS
syndrome	I-DS

65	O
/	O
252	O

83	O
/	O
253	O

119	O
/	O
253	O

145	O
/	O
253	O

Model	O
1	O

1	O

1	O
.	O
42	O
(	O
0	O
.	O
96	O
–	O
2	O
.	O
09	O
)	O

2	O
.	O
54	O
(	O
1	O
.	O
74	O
–	O
3	O
.	O
71	O
)	O

3	O
.	O
66	O
(	O
2	O
.	O
51	O
–	O
5	O
.	O
36	O
)	O

<	O
0	O
.	O
001	O

Model	O
2	O

1	O

1	O
.	O
43	O
(	O
0	O
.	O
96	O
–	O
2	O
.	O
12	O
)	O

2	O
.	O
54	O
(	O
1	O
.	O
73	O
–	O
3	O
.	O
72	O
)	O

3	O
.	O
71	O
(	O
2	O
.	O
53	O
–	O
5	O
.	O
46	O
)	O

<	O
0	O
.	O
001	O

Model	O
3	O

1	O

1	O
.	O
23	O
(	O
0	O
.	O
75	O
–	O
2	O
.	O
00	O
)	O

2	O
.	O
33	O
(	O
1	O
.	O
43	O
–	O
3	O
.	O
80	O
)	O

2	O
.	O
53	O
(	O
1	O
.	O
55	O
–	O
4	O
.	O
14	O
)	O

<	O
0	O
.	O
001	O

Model	O
4	O

1	O

1	O
.	O
25	O
(	O
0	O
.	O
76	O
–	O
2	O
.	O
06	O
)	O

2	O
.	O
22	O
(	O
1	O
.	O
35	O
–	O
3	O
.	O
65	O
)	O

2	O
.	O
41	O
(	O
1	O
.	O
46	O
–	O
3	O
.	O
97	O
)	O

<	O
0	O
.	O
001	O

Model	O
5	O

1	O

1	O
.	O
19	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
82	O
)	O

1	O
.	O
86	O
(	O
1	O
.	O
22	O
–	O
2	O
.	O
82	O
)	O

1	O
.	O
85	O
(	O
1	O
.	O
21	O
–	O
2	O
.	O
85	O
)	O

0	O
.	O
001	O

Model	O
6	O

1	O

1	O
.	O
16	O
(	O
0	O
.	O
75	O
–	O
1	O
.	O
79	O
)	O

1	O
.	O
81	O
(	O
1	O
.	O
18	O
–	O
2	O
.	O
75	O
)	O

1	O
.	O
75	O
(	O
1	O
.	O
13	O
–	O
2	O
.	O
70	O
)	O

0	O
.	O
003	O

Central	B-DS
obesity	I-DS

98	O
/	O
252	O

125	O
/	O
253	O

133	O
/	O
253	O

162	O
/	O
253	O

Model	O
1	O

1	O

1	O
.	O
51	O
(	O
1	O
.	O
06	O
–	O
2	O
.	O
16	O
)	O

1	O
.	O
71	O
(	O
1	O
.	O
20	O
–	O
2	O
.	O
44	O
)	O

2	O
.	O
75	O
(	O
1	O
.	O
91	O
–	O
3	O
.	O
95	O
)	O

<	O
0	O
.	O
001	O

Model	O
2	O

1	O

1	O
.	O
47	O
(	O
1	O
.	O
03	O
–	O
2	O
.	O
11	O
)	O

1	O
.	O
66	O
(	O
1	O
.	O
16	O
–	O
2	O
.	O
38	O
)	O

2	O
.	O
72	O
(	O
1	O
.	O
88	O
–	O
3	O
.	O
93	O
)	O

<	O
0	O
.	O
001	O

Model	O
3	O

1	O

1	O
.	O
07	O
(	O
0	O
.	O
55	O
–	O
2	O
.	O
11	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
53	O
–	O
2	O
.	O
04	O
)	O

1	O
.	O
29	O
(	O
0	O
.	O
64	O
–	O
2	O
.	O
58	O
)	O

0	O
.	O
505	O

Model	O
4	O

1	O

1	O
.	O
11	O
(	O
0	O
.	O
56	O
–	O
2	O
.	O
21	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
50	O
–	O
1	O
.	O
96	O
)	O

1	O
.	O
24	O
(	O
0	O
.	O
61	O
–	O
2	O
.	O
51	O
)	O

0	O
.	O
617	O

Model	O
5	O

1	O

1	O
.	O
26	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
86	O
)	O

1	O
.	O
16	O
(	O
0	O
.	O
78	O
–	O
1	O
.	O
71	O
)	O

1	O
.	O
39	O
(	O
0	O
.	O
92	O
–	O
2	O
.	O
10	O
)	O

0	O
.	O
160	O

Model	O
6	O

1	O

1	O
.	O
24	O
(	O
0	O
.	O
84	O
–	O
1	O
.	O
84	O
)	O

1	O
.	O
13	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
68	O
)	O

1	O
.	O
35	O
(	O
0	O
.	O
89	O
–	O
2	O
.	O
04	O
)	O

0	O
.	O
216	O

Elevated	O
blood	O
pressure	O

90	O
/	O
252	O

87	O
/	O
253	O

111	O
/	O
253	O

125	O
/	O
253	O

Model	O
1	O

1	O

0	O
.	O
96	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
40	O
)	O

1	O
.	O
40	O
(	O
0	O
.	O
96	O
–	O
2	O
.	O
02	O
)	O

1	O
.	O
59	O
(	O
1	O
.	O
10	O
–	O
2	O
.	O
30	O
)	O

0	O
.	O
004	O

Model	O
2	O

1	O

0	O
.	O
99	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
45	O
)	O

1	O
.	O
43	O
(	O
0	O
.	O
98	O
–	O
2	O
.	O
08	O
)	O

1	O
.	O
66	O
(	O
1	O
.	O
14	O
–	O
2	O
.	O
41	O
)	O

0	O
.	O
002	O

Model	O
3	O

1	O

0	O
.	O
84	O
(	O
0	O
.	O
56	O
–	O
1	O
.	O
27	O
)	O

1	O
.	O
11	O
(	O
0	O
.	O
74	O
–	O
1	O
.	O
67	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
57	O
)	O

0	O
.	O
598	O

Model	O
4	O

1	O

0	O
.	O
85	O
(	O
0	O
.	O
56	O
–	O
1	O
.	O
29	O
)	O

1	O
.	O
07	O
(	O
0	O
.	O
71	O
–	O
1	O
.	O
62	O
)	O

1	O
.	O
00	O
(	O
0	O
.	O
66	O
–	O
1	O
.	O
51	O
)	O

0	O
.	O
768	O

Model	O
5	O

1	O

0	O
.	O
87	O
(	O
0	O
.	O
59	O
–	O
1	O
.	O
30	O
)	O

1	O
.	O
15	O
(	O
0	O
.	O
78	O
–	O
1	O
.	O
69	O
)	O

1	O
.	O
07	O
(	O
0	O
.	O
72	O
–	O
1	O
.	O
60	O
)	O

0	O
.	O
515	O

Model	O
6	O

1	O

0	O
.	O
86	O
(	O
0	O
.	O
58	O
–	O
1	O
.	O
28	O
)	O

1	O
.	O
13	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
66	O
)	O

1	O
.	O
03	O
(	O
0	O
.	O
69	O
–	O
1	O
.	O
55	O
)	O

0	O
.	O
624	O

Hyperglycemia	B-DS

144	O
/	O
252	O

143	O
/	O
253	O

165	O
/	O
253	O

184	O
/	O
253	O

Model	O
1	O

1	O

0	O
.	O
95	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
36	O
)	O

1	O
.	O
36	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
95	O
)	O

1	O
.	O
89	O
(	O
1	O
.	O
29	O
–	O
2	O
.	O
75	O
)	O

<	O
0	O
.	O
001	O

Model	O
2	O

1	O

0	O
.	O
96	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
38	O
)	O

1	O
.	O
37	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
97	O
)	O

1	O
.	O
88	O
(	O
1	O
.	O
28	O
–	O
2	O
.	O
76	O
)	O

<	O
0	O
.	O
001	O

Model	O
3	O

1	O

0	O
.	O
90	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
29	O
)	O

1	O
.	O
21	O
(	O
0	O
.	O
84	O
–	O
1	O
.	O
77	O
)	O

1	O
.	O
54	O
(	O
1	O
.	O
04	O
–	O
2	O
.	O
28	O
)	O

0	O
.	O
014	O

Model	O
4	O

1	O

0	O
.	O
86	O
(	O
0	O
.	O
60	O
–	O
1	O
.	O
25	O
)	O

1	O
.	O
16	O
(	O
0	O
.	O
80	O
–	O
1	O
.	O
70	O
)	O

1	O
.	O
49	O
(	O
1	O
.	O
00	O
–	O
2	O
.	O
22	O
)	O

0	O
.	O
022	O

Model	O
5	O

1	O

0	O
.	O
92	O
(	O
0	O
.	O
64	O
–	O
1	O
.	O
32	O
)	O

1	O
.	O
23	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
79	O
)	O

1	O
.	O
54	O
(	O
1	O
.	O
03	O
–	O
2	O
.	O
29	O
)	O

0	O
.	O
017	O

Model	O
6	O

1	O

0	O
.	O
89	O
(	O
0	O
.	O
62	O
–	O
1	O
.	O
28	O
)	O

1	O
.	O
16	O
(	O
0	O
.	O
80	O
–	O
1	O
.	O
69	O
)	O

1	O
.	O
38	O
(	O
0	O
.	O
92	O
–	O
2	O
.	O
07	O
)	O

0	O
.	O
067	O

Hypertriglyceridemia	B-DS

38	O
/	O
252	O

57	O
/	O
253	O

85	O
/	O
253	O

124	O
/	O
253	O

Model	O
1	O

1	O

1	O
.	O
74	O
(	O
1	O
.	O
09	O
–	O
2	O
.	O
76	O
)	O

3	O
.	O
01	O
(	O
1	O
.	O
93	O
–	O
4	O
.	O
68	O
)	O

5	O
.	O
42	O
(	O
3	O
.	O
51	O
–	O
8	O
.	O
37	O
)	O

<	O
0	O
.	O
001	O

Model	O
2	O

1	O

1	O
.	O
77	O
(	O
1	O
.	O
11	O
–	O
2	O
.	O
82	O
)	O

3	O
.	O
07	O
(	O
1	O
.	O
96	O
–	O
4	O
.	O
79	O
)	O

5	O
.	O
55	O
(	O
3	O
.	O
58	O
–	O
8	O
.	O
61	O
)	O

<	O
0	O
.	O
001	O

Model	O
3	O

1	O

1	O
.	O
60	O
(	O
0	O
.	O
99	O
–	O
2	O
.	O
59	O
)	O

2	O
.	O
53	O
(	O
1	O
.	O
60	O
–	O
4	O
.	O
02	O
)	O

4	O
.	O
15	O
(	O
2	O
.	O
64	O
–	O
6	O
.	O
54	O
)	O

<	O
0	O
.	O
001	O

Model	O
4	O

1	O

1	O
.	O
61	O
(	O
0	O
.	O
99	O
–	O
2	O
.	O
61	O
)	O

2	O
.	O
45	O
(	O
1	O
.	O
53	O
–	O
3	O
.	O
91	O
)	O

4	O
.	O
07	O
(	O
2	O
.	O
57	O
–	O
6	O
.	O
45	O
)	O

<	O
0	O
.	O
001	O

Model	O
5	O

1	O

1	O
.	O
54	O
(	O
0	O
.	O
96	O
–	O
2	O
.	O
49	O
)	O

2	O
.	O
40	O
(	O
1	O
.	O
52	O
–	O
3	O
.	O
80	O
)	O

3	O
.	O
48	O
(	O
2	O
.	O
20	O
–	O
5	O
.	O
51	O
)	O

<	O
0	O
.	O
001	O

Model	O
6	O

1	O

1	O
.	O
52	O
(	O
0	O
.	O
94	O
–	O
2	O
.	O
46	O
)	O

2	O
.	O
34	O
(	O
1	O
.	O
47	O
–	O
3	O
.	O
71	O
)	O

3	O
.	O
32	O
(	O
2	O
.	O
09	O
–	O
5	O
.	O
28	O
)	O

<	O
0	O
.	O
001	O

Low	O
HDL	O
cholesterol	O

69	O
/	O
252	O

91	O
/	O
253	O

92	O
/	O
253	O

117	O
/	O
253	O

Model	O
1	O

1	O

1	O
.	O
51	O
(	O
1	O
.	O
03	O
–	O
2	O
.	O
21	O
)	O

1	O
.	O
58	O
(	O
1	O
.	O
08	O
–	O
2	O
.	O
31	O
)	O

2	O
.	O
51	O
(	O
1	O
.	O
72	O
–	O
3	O
.	O
67	O
)	O

<	O
0	O
.	O
001	O

Model	O
2	O

1	O

1	O
.	O
53	O
(	O
1	O
.	O
04	O
–	O
2	O
.	O
25	O
)	O

1	O
.	O
58	O
(	O
1	O
.	O
07	O
–	O
2	O
.	O
32	O
)	O

2	O
.	O
56	O
(	O
1	O
.	O
75	O
–	O
3	O
.	O
76	O
)	O

<	O
0	O
.	O
001	O

Model	O
3	O

1	O

1	O
.	O
39	O
(	O
0	O
.	O
93	O
–	O
2	O
.	O
07	O
)	O

1	O
.	O
29	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
93	O
)	O

1	O
.	O
88	O
(	O
1	O
.	O
26	O
–	O
2	O
.	O
81	O
)	O

0	O
.	O
003	O

Model	O
4	O

1	O

1	O
.	O
42	O
(	O
0	O
.	O
95	O
–	O
2	O
.	O
12	O
)	O

1	O
.	O
30	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
95	O
)	O

1	O
.	O
87	O
(	O
1	O
.	O
25	O
–	O
2	O
.	O
79	O
)	O

0	O
.	O
004	O

Model	O
5	O

1	O

1	O
.	O
38	O
(	O
0	O
.	O
92	O
–	O
2	O
.	O
05	O
)	O

1	O
.	O
24	O
(	O
0	O
.	O
83	O
–	O
1	O
.	O
86	O
)	O

1	O
.	O
63	O
(	O
1	O
.	O
08	O
–	O
2	O
.	O
45	O
)	O

0	O
.	O
034	O

Model	O
6	O

1	O

1	O
.	O
38	O
(	O
0	O
.	O
93	O
–	O
2	O
.	O
06	O
)	O

1	O
.	O
26	O
(	O
0	O
.	O
85	O
–	O
1	O
.	O
87	O
)	O

1	O
.	O
67	O
(	O
1	O
.	O
11	O
–	O
2	O
.	O
52	O
)	O

0	O
.	O
024	O

Model	O
1	O
,	O
adjusted	O
for	O
age	O
and	O
sex	O
;	O

Model	O
2	O
,	O
further	O
adjusted	O
for	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
physical	O
activity	O
,	O
educational	O
attainment	O
and	O
family	O
history	O
of	O
chronic	B-DS
diseases	I-DS
based	O
on	O
model	O
1	O
;	O

Model	O
3	O
,	O
further	O
adjusted	O
for	O
BMI	O
based	O
on	O
model	O
2	O
;	O

Model	O
4	O
,	O
further	O
adjusted	O
for	O
inflammatory	O
markers	O
(	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
)	O
based	O
on	O
model	O
3	O
.	O

Model	O
5	O
,	O
further	O
adjusted	O
for	O
insulin	B-GP
based	O
on	O
model	O
2	O
;	O

Model	O
6	O
,	O
further	O
adjusted	O
for	O
HOMA	O
-	O
IR	B-DS
based	O
on	O
model	O
2	O
.	O

In	O
joint	O
classification	O
analyses	O
,	O
rising	O
amylin	B-GP
was	O
associated	O
with	O
approximately	O
2	O
–	O
5	O
fold	O
higher	O
risk	O
of	O
MetS	B-DS
in	O
the	O
individuals	O
with	O
normal	O
-	O
weight	O
(	O
OR	O
=	O
2	O
.	O
6	O
[	O
95	O
%	O
CI	O
:	O
1	O
.	O
4	O
–	O
4	O
.	O
7	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
1	O
[	O
reference	O
group	O
],	O
Figure	O
2A	O
)	O
and	O
low	O
inflammatory	O
status	O
indicated	O
as	O
in	O
the	O
lowest	O
quartile	O
of	O
CRP	B-GP
(	O
OR	O
=	O
2	O
.	O
2	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
–	O
7	O
.	O
4	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
1	O
.	O
0	O
for	O
Q1	O
,	O
Figure	O
2B	O
),	O
IL	B-GP
-	I-GP
6	I-GP
(	O
OR	O
=	O
4	O
.	O
9	O
[	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
–	O
15	O
.	O
6	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
1	O
.	O
0	O
for	O
Q1	O
,	O
Figure	O
2C	O
),	O
insulin	B-GP
(	O
OR	O
=	O
2	O
.	O
1	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
–	O
6	O
.	O
2	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
1	O
.	O
0	O
for	O
Q1	O
,	O
Fig	O
.	O
2D	O
),	O
and	O
HOMA	O
-	O
IR	B-DS
(	O
OR	O
=	O
1	O
.	O
9	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
6	O
–	O
6	O
.	O
0	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
1	O
.	O
0	O
for	O
Q1	O
Fig	O
.	O
2E	O
).	O

However	O
,	O
the	O
risk	O
of	O
MetS	B-DS
was	O
more	O
pronounced	O
among	O
the	O
participants	O
who	O
were	O
overweight	O
/	O
obese	O
(	O
OR	O
=	O
23	O
.	O
6	O
[	O
95	O
%	O
CI	O
:	O
12	O
.	O
9	O
–	O
43	O
.	O
1	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
5	O
.	O
9	O
[	O
95	O
%	O
CI	O
:	O
3	O
.	O
3	O
–	O
10	O
.	O
5	O
]	O
for	O
Q1	O
)	O
or	O
in	O
the	O
highest	O
quartile	O
of	O
plasma	O
CRP	B-GP
(	O
OR	O
=	O
37	O
.	O
9	O
[	O
95	O
%	O
CI	O
:	O
14	O
.	O
1	O
–	O
101	O
.	O
8	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
13	O
.	O
0	O
[	O
95	O
%	O
CI	O
:	O
4	O
.	O
6	O
–	O
36	O
.	O
5	O
]	O
for	O
Q1	O
),	O
IL	B-GP
-	I-GP
6	I-GP
(	O
OR	O
=	O
35	O
.	O
9	O
[	O
95	O
%	O
CI	O
:	O
12	O
.	O
5	O
–	O
102	O
.	O
9	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
8	O
.	O
3	O
[	O
95	O
%	O
CI	O
:	O
2	O
.	O
9	O
–	O
23	O
.	O
8	O
]	O
for	O
Q1	O
),	O
insulin	B-GP
(	O
OR	O
=	O
42	O
.	O
8	O
[	O
95	O
%	O
CI	O
:	O
18	O
.	O
7	O
–	O
97	O
.	O
6	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
11	O
.	O
5	O
[	O
95	O
%	O
CI	O
:	O
4	O
.	O
2	O
–	O
31	O
.	O
9	O
]	O
for	O
Q1	O
)	O
and	O
HOMA	O
-	O
IR	B-DS
(	O
OR	O
=	O
46	O
.	O
1	O
[	O
95	O
%	O
CI	O
:	O
20	O
.	O
0	O
–	O
106	O
.	O
1	O
]	O
for	O
Q4	O
vs	O
.	O
OR	O
=	O
16	O
.	O
7	O
[	O
95	O
%	O
CI	O
:	O
5	O
.	O
9	O
–	O
47	O
.	O
3	O
]	O
for	O
Q1	O
)	O
in	O
combination	O
with	O
elevated	O
circulating	O
amylin	B-GP
.	O

No	O
significant	O
interactions	O
were	O
observed	O
between	O
amylin	B-GP
,	O
obesity	B-DS
,	O
inflammatory	O
status	O
and	O
insulin	B-DS
resistance	I-DS
on	O
the	O
risk	O
of	O
MetS	B-DS
(	O
P	O
>	O
0	O
.	O
05	O
for	O
all	O
interaction	O
tests	O
).	O

Adjusted	O
odds	O
ratios	O
for	O
MetS	B-DS
according	O
to	O
amylin	B-GP
quartiles	O
,	O
obesity	B-DS
status	O
(	O
A	O
),	O
and	O
quartiles	O
of	O
CRP	B-GP
(	O
B	O
),	O
IL	B-GP
-	I-GP
6	I-GP
(	O
C	O
),	O
insulin	B-GP
(	O
D	O
),	O
HOMA	O
-	O
IR	B-DS
(	O
E	O
).	O

Adjusted	O
for	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
physical	O
activity	O
,	O
educational	O
attainment	O
and	O
family	O
history	O
of	O
chronic	B-DS
diseases	I-DS
.	O

A	O
:	O
Modified	O
MetS	B-DS
was	O
defined	O
as	O
having	O
two	O
or	O
more	O
components	O
of	O
the	O
MetS	B-DS
without	O
central	B-DS
obesity	I-DS
.	O

Normal	O
weight	O
:	O
18	O
≤	O
BMI	O
<	O
24	O
kg	O
/	O
m2	O
;	O
overweight	O
/	O
obese	O
:	O
BMI	O
≥	O
24	O
.	O
0	O
kg	O
/	O
m2	O
.	O
P	O
=	O
0	O
.	O
105	O
for	O
interaction	O
of	O
amylin	B-GP
and	O
BMI	O
,	O
P	O
=	O
0	O
.	O
443	O
for	O
interaction	O
of	O
amylin	B-GP
and	O
CRP	B-GP
;	O
P	O
=	O
0	O
.	O
448	O
for	O
interaction	O
of	O
amylin	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
;	O
P	O
=	O
0	O
.	O
375	O
for	O
interaction	O
of	O
amylin	B-GP
and	O
insulin	B-GP
;	O
P	O
=	O
0	O
.	O
397	O
for	O
interaction	O
of	O
amylin	B-GP
and	O
HOMA	O
-	O
IR	B-DS
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
elevated	O
amylin	B-GP
concentrations	O
were	O
significantly	O
correlated	O
with	O
inflammatory	O
status	O
and	O
unfavorable	O
metabolic	O
traits	O
.	O

The	O
strong	O
positive	O
association	O
between	O
amylin	B-GP
and	O
the	O
risk	O
of	O
MetS	B-DS
was	O
independent	O
of	O
the	O
well	O
established	O
risk	O
factors	O
,	O
including	O
obesity	B-DS
,	O
inflammatory	O
markers	O
(	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
)	O
and	O
insulin	B-DS
resistance	I-DS
in	O
apparently	O
healthy	O
Chinese	O
population	O
.	O

Few	O
studies	O
have	O
examined	O
the	O
distribution	O
of	O
circulating	O
amylin	B-GP
in	O
a	O
large	O
population	O
.	O

Previously	O
,	O
Reinehr	O
et	O
al	O
reported	O
that	O
serum	O
amylin	B-GP
of	O
37	O
obese	O
children	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
16	O
health	O
lean	O
children	O
,	O
but	O
was	O
not	O
correlated	O
with	O
age	O
,	O
sex	O
and	O
BMI	O
[	O
13	O
].	O

Obese	O
persons	O
with	O
/	O
without	O
impaired	B-DS
glucose	I-DS
tolerance	I-DS
were	O
found	O
to	O
have	O
increased	O
circulating	O
amylin	B-GP
[	O
13	O
],	O
[	O
14	O
],	O
[	O
26	O
],	O
[	O
27	O
]	O
and	O
obese	O
individuals	O
also	O
tended	O
to	O
have	O
higher	O
amylin	B-GP
response	O
toward	O
glucose	O
load	O
compared	O
with	O
non	O
-	O
obese	O
individuals	O
[	O
27	O
].	O

With	O
a	O
relatively	O
large	O
sample	O
,	O
our	O
data	O
showed	O
that	O
increased	O
amylin	B-GP
concentrations	O
across	O
quartiles	O
were	O
associated	O
with	O
not	O
only	O
advanced	O
age	O
and	O
higher	O
BMI	O
,	O
but	O
also	O
unfavorable	O
metabolic	O
and	O
inflammatory	O
profiles	O
(	O
Table	O
2	O
).	O

In	O
general	O
,	O
the	O
correlations	O
were	O
stronger	O
in	O
overweight	O
/	O
obese	O
participants	O
than	O
their	O
normal	O
-	O
weight	O
counterparts	O
,	O
particularly	O
in	O
the	O
case	O
of	O
insulin	B-GP
,	O
HOMA	O
-	O
IR	B-DS
and	O
triglycerides	O
.	O

However	O
,	O
the	O
mechanistic	O
linkage	O
between	O
elevated	O
amylin	B-GP
levels	O
and	O
obesity	B-DS
related	O
metabolic	B-DS
disorders	I-DS
has	O
not	O
been	O
fully	O
understood	O
thus	O
far	O
.	O

Indeed	O
,	O
data	O
from	O
a	O
weight	O
loss	O
intervention	O
in	O
obese	O
children	O
suggested	O
that	O
changing	O
of	O
amylin	B-GP
levels	O
was	O
correlated	O
with	O
altered	O
insulin	B-GP
rather	O
than	O
change	O
of	O
BMI	O
or	O
percentage	O
of	O
body	O
fat	O
[	O
13	O
].	O

One	O
of	O
the	O
major	O
findings	O
of	O
our	O
current	O
study	O
is	O
that	O
we	O
discovered	O
a	O
strong	O
association	O
between	O
plasma	O
amylin	B-GP
and	O
the	O
risk	O
of	O
MetS	B-DS
.	O

Accumulating	O
evidence	O
,	O
mainly	O
from	O
cellular	O
and	O
animal	B-OG
studies	O
,	O
suggested	O
that	O
amylin	B-GP
plays	O
important	O
roles	O
in	O
regulating	O
food	O
intake	O
,	O
insulin	B-GP
action	O
and	O
energy	O
homeostasis	O
,	O
as	O
well	O
as	O
glucose	O
and	O
lipid	O
metabolisms	O
.	O

Moreover	O
,	O
adverse	O
effects	O
of	O
increased	O
amylin	B-GP
levels	O
on	O
metabolic	O
abnormalities	O
such	O
as	O
insulin	B-DS
resistance	I-DS
or	O
type	B-DS
2	I-DS
diabetes	I-DS
,	O
have	O
been	O
indicated	O
by	O
some	O
of	O
human	B-OG
studies	O
[	O
13	O
],	O
[	O
14	O
].	O

However	O
,	O
little	O
is	O
known	O
whether	O
high	O
circulating	O
amylin	B-GP
is	O
an	O
independent	O
risk	O
factor	O
for	O
MetS	B-DS
,	O
a	O
preclinical	O
condition	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
risk	O
of	O
CVD	B-DS
,	O
CVD	B-DS
mortality	O
,	O
and	O
stroke	B-DS
[	O
18	O
].	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
elevated	O
amylin	B-GP
per	O
se	O
is	O
associated	O
with	O
higher	O
risk	O
of	O
MetS	B-DS
even	O
in	O
normal	O
weight	O
persons	O
,	O
despite	O
the	O
fact	O
that	O
the	O
MetS	B-DS
risk	O
was	O
pronounced	O
in	O
overweight	O
/	O
obese	O
participants	O
(	O
Figure	O
2A	O
).	O

Obesity	B-DS
is	O
a	O
well	O
established	O
risk	O
factor	O
of	O
MetS	B-DS
[	O
28	O
]–[	O
30	O
].	O

Adjustments	O
for	O
BMI	O
in	O
combining	O
other	O
potential	O
confounders	O
,	O
however	O
,	O
yielded	O
only	O
a	O
minor	O
reduction	O
on	O
the	O
risk	O
of	O
MetS	B-DS
across	O
amylin	B-GP
quartiles	O
(	O
Table	O
4	O
).	O

Thus	O
,	O
the	O
amylin	B-GP
-	O
MetS	B-DS
association	O
in	O
the	O
current	O
study	O
apparently	O
could	O
not	O
mainly	O
be	O
attributed	O
to	O
obesity	B-DS
.	O

Hyperinsulinemia	B-DS
associated	O
with	O
the	O
insulin	B-DS
resistance	I-DS
of	O
obesity	B-DS
is	O
also	O
a	O
defining	O
marker	O
of	O
MetS	B-DS
.	O

Our	O
present	O
study	O
showed	O
that	O
amylin	B-GP
and	O
insulin	B-GP
were	O
both	O
elevated	O
in	O
obesity	B-DS
and	O
insulin	B-DS
resistance	I-DS
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
[	O
13	O
],	O
[	O
14	O
],	O
[	O
26	O
],	O
[	O
27	O
].	O

In	O
addition	O
,	O
we	O
found	O
that	O
amylin	B-GP
was	O
associated	O
with	O
MetS	B-DS
independent	O
of	O
hyperinsulinemia	B-DS
/	O
insulin	B-DS
resistance	I-DS
.	O

Although	O
the	O
secretion	O
of	O
amylin	B-GP
and	O
insulin	B-GP
is	O
generally	O
parallel	O
under	O
physiological	O
conditions	O
,	O
these	O
two	O
hormones	O
are	O
differently	O
regulated	O
under	O
certain	O
circumstances	O
.	O

High	O
glucose	O
increases	O
the	O
relative	O
amount	O
of	O
amylin	B-GP
to	O
insulin	B-GP
secretion	O
from	O
islets	O
isolated	O
from	O
dexamethasone	O
-	O
or	O
glucose	O
-	O
treated	O
rats	B-OG
in	O
comparison	O
with	O
islets	O
isolated	O
from	O
fed	O
and	O
fasted	O
rats	B-OG
[	O
31	O
].	O

Increased	O
storage	O
and	O
secretion	O
of	O
amylin	B-GP
relative	O
to	O
insulin	B-GP
has	O
been	O
reported	O
in	O
spontaneously	O
diabetic	O
GK	O
rats	B-OG
[	O
32	O
].	O

We	O
found	O
that	O
participants	O
in	O
the	O
higher	O
amylin	B-GP
quartile	O
had	O
higher	O
amylin	B-GP
/	O
insulin	B-GP
ratio	O
and	O
higher	O
risk	O
of	O
MetS	B-DS
,	O
supporting	O
the	O
involvement	O
of	O
amylin	B-GP
in	O
MetS	B-DS
independent	O
of	O
insulin	B-GP
.	O

Another	O
noteworthy	O
finding	O
in	O
our	O
study	O
was	O
that	O
we	O
observed	O
a	O
significantly	O
positive	O
correlation	O
between	O
amylin	B-GP
and	O
inflammatory	O
markers	O
(	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
)	O
(	O
Table	O
3	O
).	O

Low	O
-	O
grade	O
inflammation	O
is	O
one	O
of	O
the	O
widely	O
accepted	O
key	O
mechanisms	O
related	O
to	O
obesity	B-DS
,	O
insulin	B-DS
resistance	I-DS
,	O
type	B-DS
2	I-DS
diabetes	I-DS
and	O
cardiovascular	B-DS
diseases	I-DS
,	O
the	O
conditions	O
often	O
coexisted	O
with	O
hyperamylinemia	O
.	O

However	O
,	O
direct	O
evidence	O
was	O
scarce	O
regarding	O
the	O
relationship	O
between	O
amylin	B-GP
and	O
inflammation	O
.	O

In	O
our	O
recent	O
in	O
vitro	O
study	O
,	O
we	O
observed	O
that	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
a	O
proinflammatory	O
cytokine	O
elevated	O
in	O
obesity	B-DS
and	O
insulin	B-DS
resistance	I-DS
,	O
could	O
induce	O
amylin	B-GP
gene	O
expression	O
in	O
murine	O
pancreatic	O
β	O
-	O
cells	O
and	O
islets	O
,	O
and	O
also	O
could	O
activate	O
human	B-OG
amylin	B-GP
promoter	O
through	O
multiple	O
signaling	O
pathways	O
[	O
33	O
].	O

Masters	O
et	O
al	O
.	O
[	O
34	O
]	O
recently	O
reported	O
that	O
amylin	B-GP
triggered	O
the	O
NLRP3	B-GP
inflammasome	O
and	O
generated	O
mature	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
an	O
important	O
inflammatory	O
mediator	O
in	O
type	B-DS
2	I-DS
diabetes	I-DS
,	O
in	O
macrophages	O
.	O

Mice	B-OG
transgenic	O
for	O
human	B-OG
amylin	B-GP
had	O
more	O
IL	B-GP
-	I-GP
1β	I-GP
in	O
pancreatic	O
islets	O
,	O
which	O
localized	O
together	O
with	O
amyloid	O
and	O
macrophages	O
.	O

While	O
it	O
is	O
still	O
waiting	O
to	O
be	O
verified	O
whether	O
the	O
findings	O
from	O
the	O
in	O
vitro	O
and	O
animal	B-OG
studies	O
are	O
biologically	O
relevant	O
to	O
humans	B-OG
,	O
our	O
data	O
,	O
however	O
,	O
showed	O
that	O
elevated	O
amylin	B-GP
was	O
significantly	O
correlated	O
with	O
increased	O
plasma	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
.	O

Interestingly	O
,	O
like	O
in	O
the	O
case	O
of	O
obesity	B-DS
and	O
insulin	B-DS
resistance	I-DS
,	O
the	O
effect	O
of	O
CRP	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
on	O
the	O
amylin	B-GP
-	O
MetS	B-DS
association	O
was	O
rather	O
minor	O
(	O
Table	O
4	O
).	O

Together	O
,	O
this	O
data	O
again	O
suggests	O
that	O
amylin	B-GP
might	O
independently	O
promote	O
metabolic	B-DS
disorders	I-DS
through	O
the	O
mechanism	O
(	O
s	O
)	O
other	O
than	O
inflammatory	O
signaling	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
also	O
documented	O
that	O
increased	O
circulating	O
amylin	B-GP
was	O
significantly	O
associated	O
with	O
the	O
severity	O
(	O
Figure	O
1	O
)	O
and	O
each	O
component	O
of	O
MetS	B-DS
(	O
Table	O
4	O
).	O

Interestingly	O
,	O
the	O
association	O
between	O
amylin	B-GP
and	O
hypertriglyceridemia	B-DS
was	O
particularly	O
strong	O
and	O
also	O
independent	O
of	O
BMI	O
,	O
a	O
well	O
recognized	O
risk	O
factor	O
for	O
hypertriglyceridemia	B-DS
[	O
35	O
],	O
whereas	O
the	O
associations	O
between	O
amylin	B-GP
and	O
the	O
rest	O
of	O
the	O
MetS	B-DS
components	O
were	O
largely	O
explained	O
by	O
BMI	O
(	O
Table	O
4	O
).	O

Previously	O
,	O
a	O
positive	O
correlation	O
between	O
amylin	B-GP
and	O
triglycerides	O
was	O
reported	O
based	O
on	O
a	O
study	O
of	O
53	O
children	O
[	O
13	O
].	O

However	O
,	O
it	O
remains	O
controversial	O
whether	O
elevated	O
amylin	B-GP
directly	O
or	O
indirectly	O
induce	O
dyslipidemia	B-DS
or	O
vice	O
versa	O
.	O

For	O
instance	O
,	O
Smith	O
and	O
coworkers	O
reported	O
that	O
a	O
bolus	O
injection	O
or	O
infusion	O
with	O
amylin	B-GP
significantly	O
raised	O
total	O
plasma	O
triglyceride	O
levels	O
and	O
reduced	O
clearance	O
of	O
TG	O
-	O
rich	O
lipoproteins	O
by	O
about	O
45	O
%	O
[	O
36	O
].	O

In	O
another	O
study	O
,	O
Ye	O
et	O
al	O
showed	O
that	O
amylin	B-GP
infusion	O
in	O
rats	B-OG
increased	O
not	O
only	O
circulating	O
levels	O
of	O
non	O
-	O
esterified	O
fatty	O
acids	O
and	O
glycerol	O
,	O
but	O
also	O
hepatic	O
triglyceride	O
content	O
[	O
37	O
].	O

On	O
the	O
other	O
hand	O
,	O
we	O
found	O
that	O
acute	O
treatment	O
with	O
dietary	O
fatty	O
acids	O
could	O
enhance	O
amylin	B-GP
expression	O
and	O
secretion	O
in	O
murine	O
pancreatic	O
β	O
cells	O
[	O
4	O
],	O
as	O
well	O
as	O
stimulate	O
human	B-OG
amylin	B-GP
promoter	O
activation	O
.	O

Furthermore	O
,	O
acutely	O
fed	O
mice	B-OG
with	O
high	O
-	O
lipid	O
contained	O
diet	O
could	O
raise	O
plasma	O
levels	O
of	O
fatty	O
acid	O
,	O
amylin	B-GP
and	O
insulin	B-GP
in	O
a	O
temporal	O
manner	O
,	O
implicating	O
fatty	O
acid	O
might	O
play	O
a	O
critical	O
role	O
in	O
inducing	O
amylin	B-GP
release	O
[	O
4	O
].	O

The	O
discrepancies	O
might	O
be	O
due	O
to	O
inter	O
-	O
species	O
variations	O
of	O
animal	B-OG
models	O
,	O
different	O
protocols	O
and	O
doses	O
used	O
among	O
studies	O
.	O

Nonetheless	O
,	O
long	O
-	O
term	O
studies	O
,	O
especially	O
human	B-OG
studies	O
,	O
are	O
merited	O
to	O
prove	O
the	O
observations	O
from	O
acute	O
animal	B-OG
studies	O
and	O
also	O
to	O
identify	O
mechanism	O
(	O
s	O
)	O
linking	O
between	O
hyperamylinemia	O
and	O
dyslipidemia	B-DS
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
association	O
between	O
amylin	B-GP
levels	O
and	O
the	O
risk	O
of	O
MetS	B-DS
in	O
a	O
relatively	O
large	O
-	O
scale	O
population	O
.	O

Admittedly	O
,	O
due	O
to	O
the	O
cross	O
-	O
sectional	O
nature	O
of	O
current	O
study	O
,	O
we	O
can	O
not	O
establish	O
a	O
causal	O
association	O
of	O
amylin	B-GP
with	O
MetS	B-DS
risk	O
and	O
its	O
components	O
.	O

We	O
have	O
made	O
efforts	O
to	O
eliminate	O
possible	O
effects	O
of	O
most	O
potential	O
confounders	O
by	O
employing	O
strict	O
exclusion	O
criteria	O
and	O
recruiting	O
a	O
relatively	O
large	O
sample	O
of	O
apparently	O
healthy	O
adults	O
with	O
both	O
sexes	O
.	O

A	O
randomized	O
study	O
with	O
a	O
sufficiently	O
large	O
sample	O
will	O
further	O
decrease	O
the	O
potential	O
role	O
of	O
residual	O
confounding	O
.	O

Certainly	O
,	O
our	O
results	O
should	O
be	O
examined	O
in	O
longitudinal	O
studies	O
to	O
establish	O
the	O
causal	O
relationship	O
between	O
amylin	B-GP
and	O
metabolic	B-DS
syndrome	I-DS
.	O

Whether	O
increased	O
amylin	B-GP
could	O
serve	O
as	O
a	O
useful	O
biomarker	O
or	O
intervention	O
target	O
in	O
clinical	O
settings	O
for	O
predicting	O
and	O
controlling	O
metabolic	B-DS
diseases	I-DS
should	O
be	O
determined	O
prospectively	O
among	O
different	O
populations	O
.	O

In	O
summary	O
,	O
our	O
findings	O
suggest	O
that	O
elevated	O
circulating	O
amylin	B-GP
is	O
strongly	O
associated	O
with	O
MetS	B-DS
,	O
independent	O
of	O
established	O
risk	O
factors	O
including	O
obesity	B-DS
,	O
inflammatory	O
markers	O
and	O
insulin	B-DS
resistance	I-DS
in	O
apparently	O
healthy	O
Chinese	O
.	O

Our	O
results	O
also	O
provide	O
novel	O
insights	O
into	O
the	O
potential	O
role	O
(	O
s	O
)	O
of	O
amylin	B-GP
in	O
the	O
development	O
of	O
metabolic	B-DS
diseases	I-DS
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

